Skip to content

Prospective, multi-center clinical application study of MUSE endoscopic fundoplication for gastroesophageal reflux disease

Prospective, multi-center clinical application study of MUSE endoscopic fundoplication for gastroesophageal reflux disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017722
Enrollment
Unknown
Registered
2018-08-10
Start date
2018-08-10
Completion date
Unknown
Last updated
2018-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease

Interventions

Case series:Muse surgery

Sponsors

Shanghai First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years old male and female; 2. Recently (30 days) PH monitoring confirmed GERD, and PPI withdrawal; 3. Have heartburn symptoms for at least two years; 4. PPI treatment for at least 6 months, the symptoms are obviously relieved, when the PPI is stopped, there is obvious gastroesophageal reflux; 5. Esophageal manometry within 30 days showed adequate esophageal peristalsis without motor dysfunction; 6. Patients understand the research requirements and treatment procedures and sign an informed consent form (ICF) before the study begins; 7. Willing to follow all follow-up assessments; 8. In addition to GERD, good health; 9. Have the ability to read and sign ICF.

Exclusion criteria

Exclusion criteria: 1. Endoscopic findings of esophageal hiatus > 3 cm or any size of non-returnable esophageal hiatus hernia; 2. The acid exposure test results are normal (the total time of pH 35; 11. Helicobacter pylori test positive - can be enrolled after radical treatment; 12. Have the following medical history: (1) Any heart disease, NYHA cardiac function classification>1; (2) either of two types of diabetes; (3) endocrine disorders (except for hypothyroidism in drug therapy); (4) history of epilepsy, stroke, Parkinson's disease, muscular atrophic diseases such as ALS or multiple sclerosis; (5) Soft tissue condition (such as amyloidosis) that affects wound healing; (6) History of esophagus/stomach surgery (except for pyloric myotomy in children); (7) Portal hypertension caused by cirrhosis or other causes; (8) autoimmune disease (SLE, scleroderma, dermatomyositis); (9) renal failure (serum creatinine = 1.6); (10) blood disease, or taking anticoagulant drugs (heparin, excluding aspirin), aspirin is discontinued 7 days before the start of treatment and can be recovered after discharge; (11) Any type of cancer except skin cancer, the patient has not received active treatment; (12) has stomach or duodenal ulcer; 13. Recent history of unintentional weight loss; 14. Pregnancy; 15. Any medical factor that the investigator believes will lead to the patient's inability to complete the study; 16. History of alcohol abuse in six months; 17. Patients who participated in or were preparing to participate in other drug trials or equipment trials during the last 30 days or during the study period.

Design outcomes

Primary

MeasureTime frame
Reflux symptom;

Secondary

MeasureTime frame
GERD-Q scale score;

Countries

China

Contacts

Public ContactRONG

Shanghai First People's Hospital

wanrong1970@163.com+86 18917683428

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026